Presence of Rituximab Ajay K. Gopal, Stanley R. Riddell, …cancerimmunolres.aacrjournals.org/content/canimm/early/...1 Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T cells in the Presence of Rituximab Gregory A. Rufener,1 Oliver W. Press,1,4 Philip Olsen,1 Sang Yun Lee,1 Michael C. Jensen,1,2 Ajay K. Gopal,1,4 Barbara Pender,1 Lihua E. Budde,3 Jeffrey K. Rossow,1 Damian J. Green,1,4 David G. Maloney,1,4 Stanley R. Riddell,1,4 and Brian G. Till1,4 1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 2 Seattle Children’s Research Institute, Seattle, WA 3 City of Hope Medical Center, Duarte, CA 4 Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA Running title: Effect of Rituximab on CD20 CAR T Cell Function Keywords: Chimeric antigen receptors, Adoptive T cell therapy, Rituximab, Immunotherapy, Lymphoma Financial support: Damon Runyon Cancer Research Foundation (grant 49-C10) (PI: Till), Giuliani Family Foundation (PI: Press), NIH/NCI K23CA154874 (PI: Till), NIH/NCI Cancer Center Support Grant P30CA015704 both for Shared Resources (P.I.: Gary Gilliland) and also as a Recruitment Award (Sub-project PI: Till), NIDDK DK56465 (PI: Shelly Heimfeld, core resources) NIH/NCI P01CA044991, NIH/NCI K24CA184039 (PI: Gopal), Lymphoma Research Foundation MCL-1003440 (PI: Gopal), NIH/NCI K08CA151682 (PI: Green) Corresponding author: Brian G. Till Fred Hutchinson Cancer Research Center 1100 Fairview Ave N., D3-100 Seattle, WA 98109 [email protected] Phone: 206-667-7269 Fax: 206-667-1874 Potential conflicts of interest: BGT and OWP have received research funding from Roche/Genentech. MCJ and SRR have received research funding, patents and royalties, and equity ownership of Juno Therapeutics. Word count: 5008 Figures: 6 Tables: 0
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
BGT is a Damon Runyon-Pfizer Clinical Investigator (Grant 49-C10). This work was also
supported by the Giuliani Family Foundation, NIH/NCI K23CA154874, NIH/NCI Cancer Center
Support Grant P30CA015704, NIDDK DK56465, NIH/NCI P01CA044991, NIH/NCI
K24CA184039, NIH/NCI K08CA151682, and Lymphoma Research Foundation MCL-1003440.
References 1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-Targeted T
Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013;5(177):177ra38.
2. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013;121(7):1165-74.
3. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180(10):7028-38.
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73.
5. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33(6):540-9.
6. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385(9967):517-28.
7. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7(303):303ra139.
8. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121(5):1822-6.
9. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261-71.
10. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119(17):3940-50.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
11. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42.
12. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23(9):1984-92.
13. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86.
14. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013-22.
15. Pulczynski S, Boesen AM, Jensen OM. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood 1993;81(6):1549-57.
16. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83(5):1390-7.
17. Pulczynski S, Boesen AM, Jensen OM. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells--an immunofluorescence and immunoelectron microscopy study. Leuk Res 1994;18(7):541-52.
18. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18.
19. Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005;33(4):452-9.
20. Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1998;4(2):75-83.
21. Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5(2):131-8.
22. Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V, et al. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther 2000;7(12):1067-75.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
23. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 1999;6(2):300-4.
24. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5(12):3928-41.
25. Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother 2009;32(3):292-301.
26. James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 2009;114(27):5454-63.
27. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14(5):1561-70.
28. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69(2):584-91.
29. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains. Hum Gene Ther 2007;18(8):712-25.
30. Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004;9(4):577-86.
31. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells. Clin Cancer Res 2013.
32. Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, et al. Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. PLoS One 2013;8(12):e82742.
33. Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, et al. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther 2010;17(10):1244-52.
34. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity. Cancer immunology research 2014.
35. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther 2010;17(10):1206-13.
36. Bornstein GG, Queva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 2010;28(5):561-74.
37. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112(3):830-5.
38. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90(6):2188-95.
39. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99(9):3256-62.
40. Grumont R, Lock P, Mollinari M, Shannon FM, Moore A, Gerondakis S. The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 2004;21(1):19-30.
41. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9(16 Pt 1):5866-73.
42. Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009;46(11-12):2419-23.
43. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71.
44. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800.
45. Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, et al. Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 zeta Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. J Immunol 2014.
46. Alvarez-Vallina L, Russell SJ. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther 1999;10(4):559-63.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276
Published OnlineFirst April 21, 2016.Cancer Immunol Res Gregory A. Rufener, Oliver W Press, Philip Olsen, et al. Receptor-Expressing T cells in the Presence of RituximabPreserved Activity of CD20-Specific Chimeric Antigen
Updated version
10.1158/2326-6066.CIR-15-0276doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerimmunolres.aacrjournals.org/content/early/2016/04/21/2326-6066.CIR-15-0276To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 21, 2016; DOI: 10.1158/2326-6066.CIR-15-0276